Abstract
The incidence of adverse events related to type 2 diabetes mellitus (T2DM) is correlated to the degree of hyperglycemia. This relationship suggests that strict glycemic control might reduce the risk of adverse outcomes. In this commentary, we discuss a randomized, controlled trial that assessed the effect of an intensive therapy targeting a normal HbA1c level as compared with standard therapy in patients with T2DM at high risk of cardiovascular events. As compared with the standard therapy group, major cardiovascular events occurred in fewer patients in the intensive therapy group, but the total mortality was higher, which lead to the premature termination of the study after 3.5 years. Further clinical trials are needed to establish whether glucose normalization is beneficial in patients with T2DM and whether this is true for all or only subgroups of these patients. At present, patients with T2DM should be managed by a multifactorial strategy in which glucose lowering, targeted at currently recommended levels, is one of several components.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stettler C et al. (2006) Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 152: 27–38
Rydén L et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88–136
Lipscombe LL et al. (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298: 2634–2643
Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559
Gaede P et al. (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580–591
Anselmino M et al. (2008) Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease. A report from the Euro Heart Survey on Diabetes and the Heart. Eur J Cardiovasc Prev Rehab 15: 216–223
ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K Malmberg is global Medical Science Director for diabetes and obesity at AstraZeneca. The other authors declared no competing interests.
Rights and permissions
About this article
Cite this article
Rydén, L., Malmberg, K. & Mellbin, L. Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?. Nat Rev Endocrinol 5, 8–9 (2009). https://doi.org/10.1038/ncpendmet0997
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0997